New combo therapy targets Drug-Resistant lung cancer
NCT ID NCT04479306
First seen Apr 21, 2026 · Last updated Apr 23, 2026 · Updated 1 time
Summary
This early-phase trial tested two experimental drug combinations (osimertinib plus alisertib or sapanisertib) in 37 adults with advanced EGFR-mutant non-small cell lung cancer that no longer responded to osimertinib alone. The main goals were to find the safest dose and check for side effects. The study did not aim to cure the disease, but to better control it by overcoming drug resistance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.